trending Market Intelligence /marketintelligence/en/news-insights/trending/i3nc9rYXszKE0n4CWrjhNw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Axsome to raise $174M from common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Axsome to raise $174M from common stock offering

Axsome Therapeutics Inc. priced a public offering of its common stock to raise about $174 million in gross proceeds.

The New York-based biopharmaceutical company is offering 2 million shares at $87 apiece. Underwriters will also receive an option to buy up to an additional 300,000 shares.

Net proceeds from the offering, excluding the underwriters' option, are expected to be about $162.2 million.

Axsome intends to use the proceeds from this offering to fund the development of its drug candidates, clinical programs and for general corporate purposes.

The offering is scheduled to close Dec. 23.

SVB Leerink is acting as lead book-running manager for the offering. Morgan Stanley is acting as joint book-running manager for the offering.

Cantor Fitzgerald & Co., Ladenburg Thalmann & Co. Inc., SunTrust Robinson Humphrey Inc. and William Blair & Co. LLC are acting as co-lead managers for the offering. BTIG LLC and H.C. Wainwright & Co. are acting as co-managers for the offering.